Clinical Trial Update: Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating donor T-helper 2 (Th2) cell therapy to prevent graft-versus-host disease after bone marrow transplantation. The trial includes…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Graft-versus-host Disease
• Hodgkin Lymphoma
• Multiple Myeloma
• Non-hodgkin Lymphoma

Drugs mentioned

• Donor Th2 cell therapy (donor T helper 2 cells)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Chronic Lymphocytic Leukemia, Graft vs Host Disease | Phase 1 | Status: COMPLETED